Agilent Posts 8% Revenue Growth in Q3 2026, Lifts Full-Year Outlook
Event summary
- Agilent reported $1.88 billion in Q3 2026 revenue, up 8.1% year-over-year.
- Non-GAAP net income rose to $459 million, or $1.62 per share, including a $17 million tariff refund benefit.
- Life Sciences and Diagnostics Markets Group (LDG) saw the highest growth at 11% year-over-year.
- Agilent raised its full-year outlook, citing strong end markets and product launches.
- Operating margins expanded across all segments, with ACG at 34.3% and AMG at 24.9%.
The big picture
Agilent's strong Q3 2026 results reflect its strategic focus on operational discipline and innovation, positioning it to outperform in the analytical and clinical laboratory technologies sector. The company's ability to navigate geopolitical uncertainties and supply chain challenges will be critical as it aims to sustain its growth trajectory.
What we're watching
- Market Momentum
- Whether Agilent can sustain its 8% revenue growth pace amid improving end markets and stronger regional demand.
- Operational Efficiency
- How the Ignite Operating System will continue to drive margin expansion across all segments.
- Product Innovation
- The pace at which Agilent's new product launches will translate into sustained customer demand.
Related topics